Dear Colleagues,

Over 50% of New Mexicans are vaccinated against COVID-19, and the University has issued guidance that staff and faculty can begin returning to campus this summer. Therefore, the CTSC will begin transitioning back into full-time in-person operations this June, and our research efforts will continue apace. Read on in our featured stories for several impactful studies.

Our CERC group has been guiding Dr. Esme Finlay's Hospice and Palliative Medicine (HPM) study. Dr. Finlay's study explores the drivers of professional identity formulation in this relatively new field, with the goal of developing better curriculum and attracting new learners. The team plans to submit an abstract to the American Academy of Hospice and Palliative Medicine Annual Assembly in July 2021.

Our PCI team will soon begin recruiting for the Crohn's disease study led by Dr. Gulshan Parasher and Dr. Swathi Paleti. This study will compare the efficacy and safety of two promising new medications for patients who do not respond to biologic therapies. While biologic therapies have demonstrated success for some patients, some do not respond, and some who do respond lose treatment over time.

As always, we have updated information on COVID-19 funding opportunities. We encourage you to look for the weekly memos for current information and funding opportunities.

As we round the vaccination corner, we encourage everyone to sign up for the COVID-19 vaccine: [https://cvvaccine.nmhealth.org/](https://cvvaccine.nmhealth.org/). We also advise everyone to explore the University's Bring Back the Pack COVID-19 guidance: [https://bringbackthepack.unm.edu](https://bringbackthepack.unm.edu) as we return to campus.

All standard CTSC services are available. We encourage PIs to reach out to our Research Concierge (HSC-CTSCResearchConcierge@salud.unm.edu) with questions and/or to setup a consultation with the CTSC team.

We endeavor to update each section of the CTSC newsletter monthly. Every part of the CTSC is integral to our purpose and funding. Each PI has a personal, professional investment in the information we provide. Please submit that information to our team. The CTSC is here for your support.

The committed faculty, staff, and students at CTSC continue their research projects and look for innovative ways to support our communities. If you are interested in a rigorous quantitative rural research project focused on COVID-19, please contact me (RLarson@salud.unm.edu) to start a dialogue.

The Health Sciences Center Office of Research website contains information on specific research-related updates (including the Research Continuity Guidelines for both Laboratories & Research Facilities and Clinical Trial Research Faculty & Staff) and can be accessed through the following link: [https://hsc.unm.edu/research/](https://hsc.unm.edu/research/).

Should you have any questions about our assets and services, please contact the CTSC Research Concierge at HSC-CTSCResearchConcierge@salud.unm.edu. If you have any issues finding the information that you need, please reach out to the CTSC Newsletter Team and they will get back to you.

As always, thank you so much for your continued support of the Clinical & Translational Science Center!
Warm regards,

Richard S. Larson, MD, PhD
PI, CEO and Director, Clinical & Translational Science Center

CTSC Leadership

CTSC Director, CEO & Principal Investigator: Richard S. Larson, MD, PhD
Associate Director, CTSC: Matthew Campen, PhD
Associate Director, CTSC: Nancy Pandhi, MD, PhD, MPH
Chief Administrative Officer: Carla Cordova, MPH
Administrative Component Director: Beth Tiggges, PhD, RN, PNP, BC
Tracking & Evaluation Module Lead: Beth Tiggges, PhD, RN, PNP, BC
Quality & Efficiency Module Lead: Beth Tiggges, PhD, RN, PNP, BC
Informatics Component Director: Christophe Lambert, PhD
Community & Collaboration Component Director: Mark Unruh, MD
Community Engagement Module Lead: Nancy Pandhi, MD, PhD, MPH
Collaboration and Commercialization Module Lead: Eric Prossnitz, PhD
Translational Endeavors (TE) Component Director: Christopher Abbott, MD
Translational Workforce Development (TWD) Module Lead: Karlett Parra, PhD
Pilot Translational & Clinical Studies (PTC) Module Lead: Corey Ford, MD, PhD
Research Methods (RM) Component Director: Mark Unruh, MD
Biostatistics, Epidemiology & Research Design (BERD) Module Lead: Mark Unruh, MD
Regulatory Knowledge & Support (RKS) Module Lead: Corey Ford, MD, PhD
Hub Research Capacity (HRC) Component Director: Nancy Pandhi, MD, PhD, MPH
Integration of Special Populations (ISP) Module Lead: Nancy Pandhi, MD, PhD, MPH
Participant Clinical Interactions (PCI) Director: Christopher Abbott, MD
Network Capacity (NC) Component Director: Hengameh Raissy, PharmD
Trial Innovation Network (TIN) Module Lead: Hengameh Raissy, PharmD
Drug Discovery & Repurposing Core Lead: Hakim Djaballah, PhD
Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD) Module Lead: Kimberly Page, PhD, MPH
KL2 Mentored Career Development Component Director: Matt Campen, PhD
Clinical Laboratory Medical Director: Qian-Yun Zhang, MD, PhD

Featured Stories

CERC Guiding Study on Understanding Professional Identity Formation in Hospice and Palliative Medicine

Hospice and Palliative Medicine (HPM) is a relatively new field, achieving its status as a distinct specialty with board certification in 2006. The drivers of professional identity formation in HPM are not well understood. To attract more learners to the field of HPM and to develop better curriculum for medical students, residents, fellows, and faculty, Dr. Esme Finlay, Associate Professor in the Division of Palliative Medicine in the Department of Internal Medicine, and her colleagues are conducting the study “Exploring Professional Identity Formation (PIF) in Palliative Medicine.” As the team’s first research project, CERC has been guiding them through the research process, providing project management, qualitative data collection, and qualitative analysis.

Based on preliminary analysis, two interviewees share their path that led them to HPM. One interviewee highlights one specific patient experience her third year of residency:

“...I had a patient who came into the emergency room [who had been] labeled as a person who was seeking pain medications...he came in with this really horrible back pain, and it turned out that he had metastatic cancer from his lungs, which caused a fracture in his spine...I was fortunate enough to be with him throughout several weeks of his hospitalization, where he started getting treatment for his cancer. And it was just one of those moments where I really got the feeling that so much of what I had learned in medical school had been to be taught to look at people as if they were a collection of diseases. And I think it was a very humbling experience for me...what was most important was learning about who this man was and what was important to him to be able to help be alongside him throughout his treatment...And it was right then, immediately, that I knew that the type of medicine I wanted to practice was palliative medicine, even though I sort of had this sense all along that I wanted to be with people in these most intimate moments and get to know who they were to be able to make good recommendations for how we take care of them.”

The team plans to submit an abstract to the American Academy of Hospice and Palliative Medicine Annual Assembly in July 2021. This project is funded by the Scholarship in Education Allocations Committee (SEAC).
PCI Recruiting for Crohn’s Disease Study

Dr. Gulshan Parasher, Division Chief of Gastroenterology and Hepatology and Dr. Swathi Paleti, associate professor in the Department of Gastroenterology will soon begin recruitment for M20-259, A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease Who Have Failed Anti-TNF therapy. This study will examine the treatment of adults with moderate to severe Crohn’s disease (CD) by comparing the efficacy and safety of Risankizumab versus Ustekinumab.

Crohn’s disease is a chronic inflammatory bowel disease characterized by inflammation of the gastrointestinal tract. CD affects 20% of the population, and with women being affected slightly more than men. The exact cause of CD is unknown, but it is hypothesized that CD is caused by a dysregulated immune system. A patient’s genetics, microbiome, immune response and environment can result in excessive and abnormal immune response in the gut that results in CD pathology.

CD patients experience symptoms of fatigue, prolonged diarrhea, abdominal pain, weight loss and fever. Treatment has focused on controlling inflammation and reducing symptoms. However, an emerging goal is to heal the gut mucosa. Conventional therapies are limited and are not always successful at abating the inflammatory process and some have adverse effects. Recently biologic therapies, such as anti-tumor necrosis factor (TNF) and integrin inhibitors have provided clinical remission in patients. However, while biologic therapies have demonstrated success for some patients, many patients do not respond to biologic treatment or lose treatment over time. In addition, some patients are not candidates for biologic therapies. Therefore, the need for alternative therapies for CD is needed.

This study focuses on those individuals with CD who have failed TNF therapy and will examine the efficacy and safety of two drugs in this group of patients. According to the study protocol, “Risankizumab is a fully humanized monoclonal antibody of the immunoglobulin G1 subclass directed towards interleukin (IL)-23p19” while “Ustekinumab, a p40 IL-12/23 inhibitor, is approved for the treatment of moderate to severe CD”. The study hypothesizes that Risankizumab will provide non-inferior efficacy at week 24 and superior efficacy at week 48 compared to Ustekinumab.

This is a multi-site study involving approximately 32 countries, and 307 sites, with UNM HSC being one of these sites. The PCI team at CTSC is offering full-study coordination to Drs. Parasher and Paleti for this study.

If you have questions about PCI services, please contact Donna Sedillo at dsedillo@salud.unm.edu

Menu of Services & Resources

- Biostatistics Support
- Brain & Behavioral Disorders
- Citing the Clinical & Translational Science Center
- Clinical Trials Participant Clinical Interactions
- Community Engagement
- Community Health Network
- Database Mining
- Drug Repurposing
- KL2 Scholars
- Intramural Funding
- Laboratory Services
- Pilot Funding
- Trial Innovation Network
- Quality & Efficiency
- Regulatory Knowledge & Support
- Rural Health Research
- Team Science & Commercialization
- Training
- Vulnerable Populations

Administration

Tracking & Evaluation (T&E)
The Tracking and Evaluation Team is piloting a new “Common Metric” called the Median Accrual Metric. This metric is intended to look at our CTSC’s ability to recruit and retain research participants. This metric will look at the entire calendar year for 2020 and will be reported in August of 2021.

Quality & Efficiency (Q&E)
The Quality and Efficiency Team continues to work on two specific process improvements initiatives. These two projects will conclude in June of 2021 and will be evaluated for how the projects impacted our CTSC.

Informatics
CTSC National Data Sharing Networks Applied for COVID-19, Behavioral Health, and More

As a user of the Cerner medical record, the HSC is part of national data sharing networks with other institutions using the Cerner EMR. One network called the “Learning Health Network”, contains Cerner’s so-called “Real World Data” containing de-identified data on over 92 million patients. Using Real World Data, Drs. Shekhar, Rustagi and Sheikh are working with the CTSC on a series of COVID-19 studies that are enhanced by having the statistical power available from a national sized sample. Similarly, Dr. Jennifer Crawford is working with the CTSC on a CTSC pilot studying national and local behavioral health needs in women's health care settings. This data is available to all researchers on the HSC campus. To access the data, investigators work with CTSC data analysts, who have developed considerable expertise in this data.

Another network is called the SHARe network, organized by the Children's Hospital of Missouri, which is data from a much smaller subset of hospitals, but importantly has 3 digits of zip codes included so that local conditions can be identified and medical data can be enriched with geographic data.

Please contact Harry Snow (hsnow@salud.unm.edu) or Marguerite Valencia-Reed (MValencia-Reed@salud.unm.edu) if you are interested in learning more. In addition, the CTSC holds monthly information sessions about all its databases: https://redcap.link/1p3m215g.

Community & Collaboration (C&C)

Community Engagement & Research Core (CERC)
Qualitative Research Office Hours
Once a month, our Senior Qualitative Researcher Heidi Rishel Bracey holds office hours. If you would like to learn about upcoming office hours, please complete this quick form. At these meetings, you are welcome to bring any questions related to qualitative research. For the first 30 minutes, we will cover one of the following topics (subject to change); the second 30 minutes are open to discuss anything you’d like related to qualitative research.

- Basics of coding
- Basics of NVivo coding
- Running reports in NVivo
- Basics of interviewing
- Basics of focus group facilitation

Team Science & Commercialization

CTSC promotes several events a year to promote Team Science and Commercialization- including both Hackathon and BioVenture. Promoting collaboration across academic disciplines, scientists can bring together ideas and fill in gaps to help move research out of the lab and into the market.

These events bring together clinicians, engineers, entrepreneurs, programmers, scientists, and students to form teams that worked to develop healthcare innovations and design a pitch allowed participants to practice skills necessary to begin the process of commercialization, a vital step to ensure technologies can reach patients.

For additional information and to register for upcoming Synergy meetings, please visit the webpage: https://hsc.unm.edu/research/ctsc/programs/team-science.html.
Find out more about ASCEND Hub resources and activities on the ASCEND Hub website: https://ascendhub.org.

Translational Endeavors (TE)i

Translational Workforce Development (TWD)
Course Offerings and Consultations – Free of Cost
Translational Workforce Development has numerous course offerings and can even provide consultations as requested to assist you in your goals! Please request a consultation or additional information on any courses offered. The TWD team may be reached via HSC-CTSCTWTDTraining@salud.unm.edu.

For information regarding TWD, please visit our webpage: https://hsc.unm.edu/research/ctsc/training/index.html.

Pilot Awards

The UNM CTSC provides a variety of Pilot Award Programs that distribute intramural funding for clinical and translational research at the Health Sciences Center, including two rounds of funding for our standard RFAs annually. To access a Funding Calendar of CTSC opportunities, please use this link: https://hsc.unm.edu/research/ctsc/pilot-funding/funding-calendars/index.html.
Please visit our web site at [https://hsc.unm.edu/research/ctsc/pilot-funding/index.html](https://hsc.unm.edu/research/ctsc/pilot-funding/index.html) for additional information.

### Research Methods (RM)

#### Biostatistics, Epidemiology, and Research Design (BERD)

**Biostatistics Consultation Services Available at CTSC**

The Biostatistics, Epidemiology, and Research Design (BERD) Core provides consultation and services, novel tools and methods intended to solve problems, and address barriers to the conduct of clinical and translational research. Services are open to all Health Sciences investigators (staff, students, and faculty) to understand the methodological aspects of their research for planning their projects, including power analysis, sample size, and research design for intramural and extramural grant submissions.

If you have a current pilot study that requires biostatistical support, please schedule appointments as soon as possible.

Are you interested in applying for a pilot study? It is strongly recommended that you make an appointment with one of our biostatisticians prior to your submission. Our expert biostatisticians can help in the initial stages of project development.

Appointments are available; but do fill up quickly. To schedule an appointment, please contact [HSC-CTSCbiostats@salud.unm.edu](mailto:HSC-CTSCbiostats@salud.unm.edu). Services are offered Monday through Friday.

Please visit our web site: [http://hsc.unm.edu/research/ctsc/biostatistics/index.html](http://hsc.unm.edu/research/ctsc/biostatistics/index.html)

### Regulatory Knowledge & Support (RKS)

The University of New Mexico in collaboration with the Western Institutional Review Board (WIRB), allows CTSC Investigators will be able to streamline study start up activities for new clinical trials through the Clinical Research and Regulatory Support Services as well as initiate studies in a prompt and efficient manner. WIRB has been at the forefront of protecting the rights and welfare of human subjects. They provide in-depth regulatory expertise to support the development of research protocols and documentation.

WIRB is an independent IRB that has maintained full accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) since 2003. If you are interested in exploring the possibility of using WIRB in conjunction with our Regulatory Management and/or Study Coordinator services, please complete the Request for Resources Form and submit to CTSC Research Concierge at [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu).

To qualify for this service, you must obtain Departmental Review and Approval, provide a fully industry sponsored Phase II, III, or IV clinical trial, and utilize our CTSC Regulatory Support Service in addition to other CTSC Resources.

For more information please contact Rebecca Brito at [rbrito@salud.unm.edu](mailto:rbrito@salud.unm.edu)

### Hub Research Capacity (HRC)

#### Integrating Special Populations (ISP)

The aim of the CTSC ISP team is to identify, develop, and deploy strategies to involve populations who are underserved or otherwise underrepresented in all stages of research. Urging investigators to design scientifically sound CTR that includes special populations from the outset is of critical importance. To aid investigators in these efforts, ISP has developed the new specialized Rurally Engaged, Spanish speaking or Network Specialized Experts (RESPONSE) team led by experienced faculty with mixed-methods CTR expertise. This group will provide pre-proposal consultations. Consultations will focus on best practices and considerations in New Mexico’s special populations, and identify and connect investigators to potential engagement partners, collaborators, and UNM CTSC resources and services. The team coordinates closely with other CTSC cores (e.g., CERC, Translational Endeavors, KL2). Consults are currently available via web-based technology.

If you would like to request a consultation, please fill out the intake form at the following link: [https://ctctrials.health.unm.edu/redcap/surveys/?s=NNH84CWCAK](https://ctctrials.health.unm.edu/redcap/surveys/?s=NNH84CWCAK)

For more information, please contact Jesus Fuentes at [JEFuentes@salud.unm.edu](mailto:JEFuentes@salud.unm.edu)

For more information about the Integrated Special Population team, please contact Dr. Nancy Pandhi, MD, PhD, MPH at [NPandhi@salud.unm.edu](mailto:NPandhi@salud.unm.edu).

For more information on Integrating Special Populations, please use the following link: [https://hsc.unm.edu/research/ctsc/Community-Engaged-Research-Core/integrating-special-populations.html](https://hsc.unm.edu/research/ctsc/Community-Engaged-Research-Core/integrating-special-populations.html)
The Community Health Network (CHN) continues to make connections with our neighboring communities in rural New Mexico. Cynthia Killough, the program manager, has been attending about 13 Community Health Council meetings regularly since July of 2020 (represented by gold stars on map). These meetings provide a wealth of information about health disparities and concerns that are important to communities. The meetings also provide a way for Cynthia to introduce health research at UNM and help break down stigma associated with research in general. Cynthia has already been able to disseminate study results, promote studies, and talk about her work as the Community Health Specialist at CTSC via presentations to these health councils.

Network Capacity (NC)

**Trial Innovation Network (TIN)**

The Trial Innovation Network is a collaborative initiative within the CTSA Program and is composed of three key partners: the CTSA Program Hubs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).

The vision for the Trial Innovation Network is to innovatively address critical roadblocks in clinical research and accelerate the translation of novel interventions into life-saving therapies.

The Trial Innovation Network is a collaborative national network with a focus in three main areas: operational innovation, operational excellence, and collaboration. The Trial Innovation Network will leverage the expertise and resources of the CTSA Program. The Trial Innovation Network will feature a single IRB system, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement. The goal of the Trial Innovation Network is to not only execute trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand and innovate the process of conducting clinical trials.

The University of New Mexico CTSC has been a part of the Trial Innovation Network and as a result has been a participating site in several studies that impact a variety of disease states. This import work has helped connect physicians at the University of New Mexico with the clinical trials specific to their specialty. This effort has encouraged new investigators to become engaged in clinical research. This collaboration is part of the larger mission to move innovated research from the bench, to the bedside, and ultimately out into the communities in which we live.

For more information on the Trial Innovation Network, please contact George Garcia at gemgarcia@salud.unm.edu.

Drug Discovery & Repurposing Core (DDRC)

**The DDRC is a Resource for Rapidly Translating Existing Drugs into New Clinical Trials**

Do you have ideas about ways to repurpose existing FDA-approved drugs? The CTSC is here to help. Dr. Hakim Djaballah, Module Lead for the Clinical & Translational Science Center Drug Discovery and Repurposing Core (DDRC) collaborates with UNM investigators other CTSCs to improve health outcomes by providing unique resources for rapidly translating existing drugs for use in new clinical trials. DDRC provides access to and operation of state-of-the-art technology in drug rescue, repurposing, and repositioning through innovative tools that support investigators and start-up companies. Additionally, DDRC provides support and guidance in translating pilot projects from preclinical proof-of-principle to clinical proof-of-concept as well as helps to develop first-in-human clinical trials.

For additional information or to become a DDRC member, please visit the DDRC (formerly DR3N) webpage: https://hsc.unm.edu/research/ctsc/dr3n/index.html.

OpIoiD-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD)

**Save the Date: Southwest Clinical Trials Network Presentation on Buprenorphine Microdosing on June 16, 2021**

The CTSC OPIOIDD function is happy to announce the upcoming quarterly Southwest Clinical Trials Network’s Community Advisory
Group Meeting, on Thursday June 16th 2021 from 12:00-1:00pm. Special Focus of the CAG: Dr. Larry Leeman will present about the exciting new Buprenorphine Microdosing protocol currently being piloted in the UNM Milagro Clinic. A buprenorphine micro-dosing protocol carries the benefits of avoiding the need for pregnant patients to enter withdrawal, and occurring outpatient regardless of gestational age. A Q&A session will follow the presentation.

All are welcome to attend this important meeting. To register, please visit: https://hsc-unm.zoom.us/meeting/register/tJckf-moqT4rH9x-Kw0-dE6hga26f46jd7HH

For more information, please contact Dr. Page at pagek@salud.unm.edu.

Clinical Laboratory (T-Laboratory)

T-Lab Has a New Spectrophotometer Instruments
The CTSC’s T-Lab has purchased a new spectrophotometer instrument. The NanoDrop One is the next generation instrument in the NanoDrop series of microvolume UV-Vis spectrophotometers. NanoDrop spectrophotometers use a microvolume sample retention system to minimize sample consumption and eliminate the need for cuvettes. A variable, auto-range pathlength feature allows users to measure up to 366x higher sample concentrations than can be measured in a 10 mm cuvette making dilution steps unnecessary.

The NanoDrop One does everything that its predecessors can and more, including:

- On-board instrument control via a touch screen display
- A broader dynamic range (up to 27,500 ng/μL dsDNA)
- Expanded connectivity and data management options
- Enhanced sample analysis and technical support with Acclaro Sample Intelligence technology

For questions, please contact HSC-CTSCResearchConcierge@salud.unm.edu.

Funding Opportunities Specific to COVID-19
There are several significant funding opportunities available through the CTSC to address the COVID-19 pandemic. CTSC monitors these opportunities for our HSC faculty on a weekly basis and includes additional information from the NIH COVID-19 funding site for your convenience.

Some of these funding opportunities require an active grant or cooperative agreement. They may also need a Letter of Support from Dr. Larson, the CTSC PI. Please contact Michelle Parra (MMParra@salud.unm.edu) if you are interested in applying for any of the COVID-19 funding opportunities listed below.

Recent Active Funding Opportunities Specific to COVID-19 are listed below:

<table>
<thead>
<tr>
<th>Title</th>
<th>Notice Number</th>
<th>Organization(s)</th>
<th>Release Date</th>
<th>RFA/PA/PAR #</th>
<th>Expiration Date</th>
<th>Activity Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2</td>
<td>NOT-DA-21-019</td>
<td>NIDA</td>
<td>Feb 10, 2021</td>
<td>PA-20-184</td>
<td>PA-20-183</td>
<td>PA-20-200</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders</td>
<td>NOT-DA-21-041</td>
<td>NIDA</td>
<td>Apr 15, 2021</td>
<td>PA-20-272</td>
<td>PA-18-935 (Urgent Supplement)</td>
<td>Mar 31, 2022</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</td>
<td>RFA-OD-21-008</td>
<td>NIH, NIBIB, NIDDK, NIEHS, NIMH, NINDS, NINR, NIA, NIAAA, NIDCD, NIDA, NIMHD, NLM, OBSSR, ODP, SGMRO, THRO, NIDCR, NHLBI, ECHO, NICHD, NCI, NCATS, NCCIH, NEI, NHGRI, NIAID, NIAMS, NIGMS, ORWH</td>
<td>Apr 13, 2021</td>
<td>RFA-OD-21-009, U01</td>
<td>Research Project (Cooperative Agreements)</td>
<td>NOT-OD-21-103</td>
</tr>
<tr>
<td>Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional)</td>
<td>NOT-DA-21-017</td>
<td>NIDA</td>
<td>Feb 4, 2021</td>
<td>PA-20-184</td>
<td>PA-20-183</td>
<td>PA-20-200</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</td>
<td>NOT-AI-21-008</td>
<td>NIAID</td>
<td>Feb 4, 2021</td>
<td>PA-20-185</td>
<td>PA-20-195</td>
<td>Jan 8, 2023</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)</td>
<td>NOT-DA-21-018</td>
<td>NIDA</td>
<td>Feb 3, 2021</td>
<td>PA-20-184</td>
<td>PA-20-183</td>
<td>PA-20-200</td>
</tr>
<tr>
<td>Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)</td>
<td>RFA-AI-20-078</td>
<td>NIAID, NIEHS</td>
<td>Jan 12, 2021</td>
<td>RFA-AI-20-078</td>
<td>Jun 5, 2021</td>
<td>U19</td>
</tr>
<tr>
<td>Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)</td>
<td>RFA-AI-20-077</td>
<td>NIAID, NIEHS</td>
<td>Jan 12, 2021</td>
<td>RFA-AI-20-077</td>
<td>Jun 5, 2021</td>
<td>U01</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities</td>
<td>NOT-MD-21-008</td>
<td>NIMHD, NIAID, NIAMS, NCI, ORWH, NIMH, NIH, OBSSR, ODP, NHLBI, NIDCR, SGMRO</td>
<td>Dec 17, 2020</td>
<td>PA-20-183, PA-20-185</td>
<td>Jan 8, 2022</td>
<td>R01</td>
</tr>
<tr>
<td>Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects</td>
<td>NOT-AI-21-002</td>
<td>NIAID</td>
<td>Nov 10, 2020</td>
<td>PAR-20-072</td>
<td>Jun 12, 2021</td>
<td>PO1</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection</td>
<td>NOT-DA-20-084</td>
<td>NIDA</td>
<td>Oct 27, 2020</td>
<td>PA-20-183, PA-20-200, PA-20-195</td>
<td>Sep 8, 2024</td>
<td>R01, R03, R21</td>
</tr>
<tr>
<td>Mobile Health Solutions to rectify digital inequality in communities affected by</td>
<td>RFA-DA-22-001</td>
<td>NIDA</td>
<td>Apr 27, 2021</td>
<td>R43/R44</td>
<td>Aug 14, 2021</td>
<td>R43/R44</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2</td>
<td>NOT- AI-20-065</td>
<td>NIAID</td>
<td>Aug 13, 2020</td>
<td>PAR-18-633</td>
<td>Sep 1, 2021</td>
<td>U01</td>
</tr>
<tr>
<td>Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)</td>
<td>PAR-20-256</td>
<td>NIAID</td>
<td>Jul 13, 2020</td>
<td>PAR-20-256</td>
<td>Jul 8, 2021</td>
<td>S10</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</td>
<td>NOT- AI-20-059</td>
<td>NIAID</td>
<td>Jul 6, 2020</td>
<td>PA-20-135</td>
<td>Jul 2, 2021</td>
<td>333</td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus</td>
<td>NCATS</td>
<td>Apr 9, 2020</td>
<td>PA-20-135</td>
<td>Jan 26, 2022</td>
<td>333</td>
<td></td>
</tr>
<tr>
<td>Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus</td>
<td>NCATS</td>
<td>Apr 9, 2020</td>
<td>PA-18-591</td>
<td>Jan 26, 2022</td>
<td>333</td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>Code</td>
<td>Institutions</td>
<td>Start Date</td>
<td>Code</td>
<td>End Date</td>
<td>Award Type</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>---------------</td>
<td>------------------------------------------------------------------------------</td>
<td>------------</td>
<td>---------------</td>
<td>-----------</td>
<td>------------</td>
</tr>
<tr>
<td>Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)</td>
<td>PA-20-135</td>
<td>NIH, NCATS, NCCIH, NCI, NHGRI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICH, NIDCD, NIDDK, NIEHS, NGMS, NIMH, NIMHD, NINR, NLM, ORWH, OSC</td>
<td>Mar 10, 2020</td>
<td>PA-20-135</td>
<td>Sep 8, 2025</td>
<td>333</td>
</tr>
<tr>
<td>The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)</td>
<td>RFA-OD-19-029</td>
<td>ORWH, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIDA, NICD, NIEHS, NIMH, NINR</td>
<td>Sep 27, 2019</td>
<td>PA-20-272</td>
<td>Nov 27, 2021</td>
<td>R01</td>
</tr>
<tr>
<td>Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)</td>
<td>RFA-AG-21-035</td>
<td>NIA, ORWH, OBSSR</td>
<td>Apr 8, 2021</td>
<td>PAR-21-213, U01</td>
<td>Jun 10, 2021</td>
<td>U24</td>
</tr>
<tr>
<td>Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)</td>
<td>PAR-21-213</td>
<td>NIA, NIDA, ORWH, NIMH, NIAA, NIMHD, OBSSR, NEI</td>
<td>Apr 6, 2021</td>
<td>U01 Research Project (Cooperative Agreements)</td>
<td>Nov 9, 2021</td>
<td>U01</td>
</tr>
</tbody>
</table>

If you are interested in applying for any of the grants, please email Michelle Parra (MMParra@salud.unm.edu).

For a full listing of COVID-19 through NIH, please access the following site: [https://grants.nih.gov/grants/guide/COVID-Related.cfm](https://grants.nih.gov/grants/guide/COVID-Related.cfm).

**Citing the CTSC**

When citing the CTSC, please be sure to include our Grant numbers:
Thank you!

<table>
<thead>
<tr>
<th>HS in the News</th>
</tr>
</thead>
<tbody>
<tr>
<td>For additional Health Sciences news, please visit: <a href="http://hscnews.unm.edu/">http://hscnews.unm.edu/</a></td>
</tr>
</tbody>
</table>

**News or corrections?**  
Please contact the Newsletter Team.

The University Of New Mexico Mailing Address:  
One University of New Mexico  
MSC 08 4635  
Albuquerque, NM 87131